SMAD2 and breast cancer: EW-7197 is a potent, selective, orally bioeffective TGFβ receptor ALK4/ALK5 inhibitor that can inhibit TGFβ-induced Smad2 or Smad3 phosphorylation and epithelial to mesenchymal transition (EMT) in TGFβ-treated breast cancer cells [53].